Equillium (Equillium) 3-Year FCF Growth Rate : 19.80% (As of Dec. 2023)

View and export this data going back to 2018. Start your Free Trial

What is Equillium 3-Year FCF Growth Rate?

Equillium's Free Cash Flow per Share for the three months ended in Dec. 2023 was $-0.16.

During the past 3 years, the average Free Cash Flow per Share Growth Rate was 19.80% per year. During the past 5 years, the average Free Cash Flow per Share Growth Rate was 12.90% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Free Cash Flow per Share growth rate.

During the past 7 years, the highest 3-Year average Free Cash Flow per Share Growth Rate of Equillium was 41.40% per year. The lowest was -21.60% per year. And the median was 19.80% per year.

Competitive Comparison of Equillium's 3-Year FCF Growth Rate

For the Biotechnology subindustry, Equillium's 3-Year FCF Growth Rate, along with its competitors' market caps and 3-Year FCF Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Equillium's 3-Year FCF Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Equillium's 3-Year FCF Growth Rate distribution charts can be found below:

* The bar in red indicates where Equillium's 3-Year FCF Growth Rate falls into.

Equillium 3-Year FCF Growth Rate Calculation

This is the 3-year average growth rate of Free Cash Flow per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Free Cash Flow per Share growth rate.

Equillium (NAS:EQ) 3-Year FCF Growth Rate Explanation

Free Cash Flow per Share is the amount of Free Cash Flow per outstanding share of the company's stock. Free Cash Flow is considered one of the most important parameters to measure a company's earnings power by value investors because it is not subject to estimates of Depreciation, Depletion and Amortization (DDA). However, when we look at the Free Cash Flow, we should look from a long term perspective, because any year's Free Cash Flow can be drastically affected by the spending on Property, Plant, & Equipment (PPE) of the business in that year. Over the long term, Free Cash Flow should give pretty good picture on the real earnings power of the company. It's used in the calculation of Forward Rate of Return (Yacktman) %.

Equillium 3-Year FCF Growth Rate Related Terms

Thank you for viewing the detailed overview of Equillium's 3-Year FCF Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Equillium (Equillium) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Equillium Inc (NAS:EQ) » Definitions » 3-Year FCF Growth Rate

Comparable Companies

Traded in Other Exchanges

0FY:Germany

Address

2223 Avenida De La Playa, Suite 105, La Jolla, CA, USA, 92037

Website

https://www.equilliumbio.com

Equillium Inc is a biotechnology developing therapies to treat autoimmune and inflammatory disorders. Its pipeline includes itolizumab, a first-in-class antibody targeting the CD6-ALCAM pathway which plays a key role in the modulation of effector T cells - currently in a Ph 3 study for patients with acute graft-versus-host disease and a Ph 1b study for patients with lupus nephritis. EQ101, a first-in-class cytokine inhibitor that selectively targets IL-2, IL-9, and IL-15 is Ph 2 ready and expected to begin enrolling patients in an alopecia areata study in 2H 2022. EQ102, a cytokine inhibitor that selectively targets IL-15 and IL-21, is ready for clinical development and expected to begin enrolling patients in a Ph 1study including patients with celiac disease.

Executives

Jason A Keyes	officer: Chief Financial Officer	3344 NORTH TORREY PINES COURT, SUITE 200, LA JOLLA CA 92037
Barbara Troupin	director	C/O EQUILLIUM, INC., 2223 AVENIDA DE LA PLAYA, SUITE 105, LA JOLLA CA 92037
Christine Zedelmayer	officer: Sr. Vice President and COO	2223 AVENIDA DE LA PLAYA, SUITE 105, LA JOLLA CA 92037
Stephen Connelly	director, officer: Chief Scientific Officer	2223 AVENIDA DE LA PLAYA, SUITE 108, LA JOLLA CA 92037
Decheng Capital Management Iv (cayman), Llc	10 percent owner	P.O. BOX 309, UGLAND HOUSE, GRAND CAYMAN E9 KY1-1104
Decheng Capital Global Life Sciences Fund Iv, L.p.	10 percent owner	C/O MAPLES CORPORATE SERVICES LIMITED, UGLAND HOUSE, P.O. BOX 309, GRAND CAYMAN E9 KY1-1104
Xiangmin Cui	10 percent owner	NO. 14 EAST HUSHAN ROAD, TAI'AN CITY, SHANDONG F4 000000
Yu (katherine) Xu	director	P.O. BOX 309, UGLAND HOUSE, GRAND CAYMAN E9 KY1-1104
Joel Rothman	officer: Chief Development Officer	2223 AVENIDA DE LA PLAYA, SUITE 105, LA JOLLA CA 92037
Dolca Thomas	officer: Chief Medical Officer	C/O PRINCIPIA BIOPHARMA INC., 220 E. GRAND AVENUE, SOUTH SAN FRANCISCO CA 94080
Bala S Manian	director	1025 TERRA BELLA AVE, MOUNTAIN VIEW CA 94043
Charles Douglas Mcdermott	director	100 BEAVER STREET, SUITE 201, WALTHAM MA 02453
Krishna R Polu	officer: Chief Medical Officer	C/O RAPTOR PHARMACEUTICAL CORP, 7 HAMILTON LANDING, SUITE 100, NOVATO CA 94949
Sa Biocon	10 percent owner	CO BDO SA, RUE DE LAVENIR 2, DELEMONT V8 2800
Bruce D. Steel	director, officer: President, CBO	C/O ZOSANO PHARMA CORPORATION, 34790 ARDENTECH COURT, FREMONT CA 94555